Lilly’s solanezumab fails to meet Phase II/III goal in Alzheimer’s
Brain Inflammation from Alzheimer’s disease. Credit: National Institute on Aging, NIH.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more